Balanced news tone
News Sentiment
6855 sentiment intelligence
Ascentage Pharma Group International news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
89/100 classification confidence.
directly relevant articles
high-authority source matches
-1.4% over one week, +4.2% over four weeks, trend inactive, and near fair-value range.
Ascentage Pharma Corrects AGM Date for Share Incentive Scheme Mandate
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Ascentage Pharma Corrects AGM Date for Share Incentive Scheme Mandate
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 00:15
- Source
- TipRanks
Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jun 2026 07:00
- Source
- simplywall.st
A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- Market source
Analysts Have Lowered Expectations For Ascentage Pharma Group International (HKG:6855) After Its Latest Results
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 28 Mar 2026 07:00
- Source
- webull.com
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2025 07:00
- Source
- GlobeNewswire
Ascentage Pharma Appoints Dr. Veet Misra as CFO and Eric Huang as SVP of Global Corporate Development and Finance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2025 07:00
- Source
- citybiz
Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 15:42
- Source
- Stock Titan
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 Mar 2025 07:00
- Source
- GlobeNewswire
Wilson Sonsini Advises Ascentage Pharma on U.S. Initial Public Offering and Nasdaq Listing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jan 2025 08:00
- Source
- Wilson Sonsini
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jan 2025 08:00
- Source
- MedCity News
Rockville's Ascentage Pharma seeks to raise $134M in U.S. IPO
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jan 2025 08:00
- Source
- The Business Journals
Ascentage prices first biotech IPO of 2025, raising $126M
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jan 2025 08:00
- Source
- BioPharma Dive
Ascentage Pharma sets terms for $149 million US IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jan 2025 08:00
- Source
- The Pharma Letter
BMS, Takeda's Chinese partners file for IPOs, sending Ascentage, Biokin and Bao bundling toward listings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jan 2025 08:00
- Source
- Fierce Biotech
Ascentage Pharma Received US$100 Million Option Payment from Takeda
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2024 07:00
- Source
- Macau Business
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2024 07:00
- Source
- PR Newswire
Ascentage Pharma signs R&D, commercialization deal worth up to $245M
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 15 Jul 2021 07:00
- Source
- The Business Journals